<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02306772</url>
  </required_header>
  <id_info>
    <org_study_id>TP0501</org_study_id>
    <nct_id>NCT02306772</nct_id>
  </id_info>
  <brief_title>TP0501 - Pharmaco-Scintigraphic-Study</brief_title>
  <official_title>An Open Label, Single-site Pharmaco-Scintigraphic Study in Healthy Subjects With Radio-labelled TP05-tablets (Mesalazine) to Evaluate the Gastrointestinal Transit and Release Profiles of Two Different Formulations.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tillotts Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tillotts Pharma AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase I, open-label, single-site trial to evaluate the drug release, using&#xD;
      Scintigraphic images and mesalazine plasma levels (PK) in healthy subjects. Overall, nine [9]&#xD;
      subjects per prototype coating (a total of 18) will be evaluated. Eligible subjects will be&#xD;
      assigned in a 1:1 ratio to receive radio-labelled TP05; the first 9 subjects will receive&#xD;
      formulation B and the second 9 subjects will receive formulation A. The subjects will be&#xD;
      treated once with the radio-labelled study medication.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tablet release</measure>
    <time_frame>3 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximal Plasma Concentration (Cmax)</measure>
    <time_frame>3 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach Cmax (Tmax)</measure>
    <time_frame>3 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve</measure>
    <time_frame>3 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination rate constant (k)</measure>
    <time_frame>3 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lag time (t-lag)</measure>
    <time_frame>3 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>Formulation A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TP05 Coating A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Formulation B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TP05 Coating B</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TP05 Coating A</intervention_name>
    <description>One radio-labelled tablet given to subjects</description>
    <arm_group_label>Formulation A</arm_group_label>
    <other_name>Mesalazine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TP05 Coating B</intervention_name>
    <description>One radio-labelled tablet given to subjects</description>
    <arm_group_label>Formulation B</arm_group_label>
    <other_name>Mesalazine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy subjects, male or non-pregnant, non-lactating females, between 18 and 55 years&#xD;
             old. Females of child bearing potential must have a negative serum pregnancy test&#xD;
             prior to the intake of study drug, and must use a hormonal (oral, implantable or&#xD;
             injectable) or a double barrier method of birth control throughout the study. Females&#xD;
             unable to bear children must have documentation of such in the source records (i.e.,&#xD;
             tubal ligation, hysterectomy, or post-menopausal [defined as a minimum of one year&#xD;
             since the last menstrual period]).&#xD;
&#xD;
          2. Ability of subject to participate fully in all aspects of this clinical trial.&#xD;
&#xD;
          3. Voluntarily signed informed consent must be obtained and documented.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Participating in a clinical study involving investigational drugs or dosage forms&#xD;
             within the previous 2 months.&#xD;
&#xD;
          2. History of alcohol or drug abuse.&#xD;
&#xD;
          3. Radiation exposure from clinical trials, including that from the present study and&#xD;
             from diagnostic X-ray but excluding background radiation, exceeds 5 mSV in the last 12&#xD;
             months or 10 mSv in the last 5 years. No subject whose occupational exposure is&#xD;
             monitored will participate in the study.&#xD;
&#xD;
          4. Any nuclear medicine procedure prior to study day 1 that might interfere with the&#xD;
             scintigraphic images that are acquired.&#xD;
&#xD;
          5. Clinically significant abnormal biochemistry, haematology or urine analyses:&#xD;
&#xD;
               -  White blood count &lt; 3 x 109/L and &gt; 8 x 109/L&#xD;
&#xD;
               -  Lymphocyte count &lt; 0.85 x 109/L&#xD;
&#xD;
               -  Haemoglobin &lt; 110 g/L&#xD;
&#xD;
               -  Platelet count &lt; 125 x 109/L or &gt; 600 x 109/L&#xD;
&#xD;
               -  Alanine-Aminotransferase (ALT) or Aspartate-Aminotransferase (AST) &gt; 2x upper&#xD;
                  limit normal&#xD;
&#xD;
               -  Alkaline Phosphatase &gt; 2x upper limit normal&#xD;
&#xD;
               -  Serum Creatinine &gt; upper limit normal&#xD;
&#xD;
          6. History of gastrointestinal surgery, with the exception of appendectomy unless it was&#xD;
             performed within the previous 12 months.&#xD;
&#xD;
          7. History of cardiovascular, renal, hepatic, respiratory and particularly&#xD;
             gastrointestinal disease, especially peptic ulceration, gastrointestinal bleeding,&#xD;
             ulcerative colitis, Crohn's disease or Irritable Bowel Syndrome (within the previous&#xD;
             12 months).&#xD;
&#xD;
          8. History of adverse reaction or allergy to Mesalazine or other salicylates.&#xD;
&#xD;
          9. Acute diarrhoea or constipation in the 14 days before the predicted first study day.&#xD;
             If screening occurs &gt;14 days before first study day, this criterion is to be&#xD;
             determined on the first study day. Diarrhoea will be defined as the passage of liquid&#xD;
             faeces and/or qa stool frequency of &gt; 3 times per day. Constipation will be defined as&#xD;
             a failure to open the bowels more frequently than every other day.&#xD;
&#xD;
         10. Donation of blood within the previous three months.&#xD;
&#xD;
         11. Positive HBV-Antigen (Hepatitis-B), HCV-Antibody (Hepatitis-C) or HIV-Antibody (Human&#xD;
             Immunodeficiency Virus) results.&#xD;
&#xD;
         12. Over-the-counter (OTC) and prescription medication (including laxatives, vitamin-pills&#xD;
             and natural herbal remedies) between screening visit (visit 1) and completion of the&#xD;
             study. Occasional paracetamol or acetyl-salicyl-acid is permitted.&#xD;
&#xD;
         13. Failure to satisfy the Principle Investigator to participate for any other reason.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>November 2014</verification_date>
  <study_first_submitted>October 15, 2014</study_first_submitted>
  <study_first_submitted_qc>December 1, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 3, 2014</study_first_posted>
  <last_update_submitted>December 1, 2014</last_update_submitted>
  <last_update_submitted_qc>December 1, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 3, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis, Ulcerative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mesalamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

